N/A
N=25
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Bottom Line
View on ClinicalTrials.gov: NCT01319318 ↗Enrolled (actual)
25
Serious AEs
4.0%
Results posted
Jul 2013
Primary outcome: Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Pars Plana Vitrectomy (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Vitreous Cell Count of 0 |
88.0 | — |
Summary
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
Eligibility Criteria
Inclusion Criteria
- Require pars plana vitrectomy in at least 1 eye
- Best corrected visual acuity in the study eye between 20/400 and 20/40
Exclusion Criteria
- Use of any NSAIDs (topical or systemic) within 14 days
- Use of topical or systemic steroids within 30 days
- Active eye infection in either eye
- Any eye surgery within 6 months
- Prior pars plana vitrectomy, YAG capsulotomy or uveitis
Data sourced from ClinicalTrials.gov (NCT01319318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.